143 related articles for article (PubMed ID: 29323899)
1. Optimization of Potent and Selective Tricyclic Indole Diazepinone Myeloid Cell Leukemia-1 Inhibitors Using Structure-Based Design.
Shaw S; Bian Z; Zhao B; Tarr JC; Veerasamy N; Jeon KO; Belmar J; Arnold AL; Fogarty SA; Perry E; Sensintaffar JL; Camper DV; Rossanese OW; Lee T; Olejniczak ET; Fesik SW
J Med Chem; 2018 Mar; 61(6):2410-2421. PubMed ID: 29323899
[TBL] [Abstract][Full Text] [Related]
2. Discovery of tricyclic indoles that potently inhibit Mcl-1 using fragment-based methods and structure-based design.
Burke JP; Bian Z; Shaw S; Zhao B; Goodwin CM; Belmar J; Browning CF; Vigil D; Friberg A; Camper DV; Rossanese OW; Lee T; Olejniczak ET; Fesik SW
J Med Chem; 2015 May; 58(9):3794-805. PubMed ID: 25844895
[TBL] [Abstract][Full Text] [Related]
3. 1-Phenyl-1H-indole derivatives as a new class of Bcl-2/Mcl-1 dual inhibitors: Design, synthesis, and preliminary biological evaluation.
Xu G; Liu T; Zhou Y; Yang X; Fang H
Bioorg Med Chem; 2017 Oct; 25(20):5548-5556. PubMed ID: 28866374
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 2-Indole-acylsulfonamide Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods.
Pelz NF; Bian Z; Zhao B; Shaw S; Tarr JC; Belmar J; Gregg C; Camper DV; Goodwin CM; Arnold AL; Sensintaffar JL; Friberg A; Rossanese OW; Lee T; Olejniczak ET; Fesik SW
J Med Chem; 2016 Mar; 59(5):2054-66. PubMed ID: 26878343
[TBL] [Abstract][Full Text] [Related]
5. Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design.
Friberg A; Vigil D; Zhao B; Daniels RN; Burke JP; Garcia-Barrantes PM; Camper D; Chauder BA; Lee T; Olejniczak ET; Fesik SW
J Med Chem; 2013 Jan; 56(1):15-30. PubMed ID: 23244564
[TBL] [Abstract][Full Text] [Related]
6. Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors.
Lee T; Bian Z; Zhao B; Hogdal LJ; Sensintaffar JL; Goodwin CM; Belmar J; Shaw S; Tarr JC; Veerasamy N; Matulis SM; Koss B; Fischer MA; Arnold AL; Camper DV; Browning CF; Rossanese OW; Budhraja A; Opferman J; Boise LH; Savona MR; Letai A; Olejniczak ET; Fesik SW
FEBS Lett; 2017 Jan; 591(1):240-251. PubMed ID: 27878989
[TBL] [Abstract][Full Text] [Related]
7. Fragment-Based Design, Synthesis, and Biological Evaluation of 1-Substituted-indole-2-carboxylic Acids as Selective Mcl-1 Inhibitors.
Wang Z; Xu W; Song T; Guo Z; Liu L; Fan Y; Wang A; Zhang Z
Arch Pharm (Weinheim); 2017 Jan; 350(1):. PubMed ID: 27911011
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and preliminary biological evaluation of indole-3-carboxylic acid-based skeleton of Bcl-2/Mcl-1 dual inhibitors.
Liu T; Wan Y; Liu R; Ma L; Li M; Fang H
Bioorg Med Chem; 2017 Mar; 25(6):1939-1948. PubMed ID: 28233676
[TBL] [Abstract][Full Text] [Related]
9. Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer.
Lee T; Christov PP; Shaw S; Tarr JC; Zhao B; Veerasamy N; Jeon KO; Mills JJ; Bian Z; Sensintaffar JL; Arnold AL; Fogarty SA; Perry E; Ramsey HE; Cook RS; Hollingshead M; Davis Millin M; Lee KM; Koss B; Budhraja A; Opferman JT; Kim K; Arteaga CL; Moore WJ; Olejniczak ET; Savona MR; Fesik SW
J Med Chem; 2019 Apr; 62(8):3971-3988. PubMed ID: 30929420
[TBL] [Abstract][Full Text] [Related]
10. Discovery and structure-activity relationship studies of N-substituted indole derivatives as novel Mcl-1 inhibitors.
Luan S; Ge Q; Chen Y; Dai M; Yang J; Li K; Liu D; Zhao L
Bioorg Med Chem Lett; 2017 May; 27(9):1943-1948. PubMed ID: 28343875
[TBL] [Abstract][Full Text] [Related]
11. Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling.
Grundy M; Seedhouse C; Jones T; Elmi L; Hall M; Graham A; Russell N; Pallis M
PLoS One; 2018; 13(1):e0190682. PubMed ID: 29298347
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of dual Bcl-2/Mcl-1 inhibitors bearing 2-(1H-indol-4-yl)benzoic acid scaffold.
Niu Q; Deng H; Zhang Z; Xu Q; Luan S; Huang M; Liu D; Zhao L
Bioorg Med Chem Lett; 2021 Sep; 47():128215. PubMed ID: 34153472
[TBL] [Abstract][Full Text] [Related]
13. Discovery and structure-activity relationship studies of novel Bcl-2/Mcl-1 dual inhibitors with indole scaffold.
Zhang Z; Hou L; Bai L; Pei J; Zhao S; Luan S; Liu D; Huang M; Zhao L
Bioorg Chem; 2022 Aug; 125():105845. PubMed ID: 35512494
[TBL] [Abstract][Full Text] [Related]
14. Structure-Guided Discovery of a Selective Mcl-1 Inhibitor with Cellular Activity.
Szlávik Z; Ondi L; Csékei M; Paczal A; Szabó ZB; Radics G; Murray J; Davidson J; Chen I; Davis B; Hubbard RE; Pedder C; Dokurno P; Surgenor A; Smith J; Robertson A; LeToumelin-Braizat G; Cauquil N; Zarka M; Demarles D; Perron-Sierra F; Claperon A; Colland F; Geneste O; Kotschy A
J Med Chem; 2019 Aug; 62(15):6913-6924. PubMed ID: 31339316
[TBL] [Abstract][Full Text] [Related]
15. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).
Leverson JD; Zhang H; Chen J; Tahir SK; Phillips DC; Xue J; Nimmer P; Jin S; Smith M; Xiao Y; Kovar P; Tanaka A; Bruncko M; Sheppard GS; Wang L; Gierke S; Kategaya L; Anderson DJ; Wong C; Eastham-Anderson J; Ludlam MJ; Sampath D; Fairbrother WJ; Wertz I; Rosenberg SH; Tse C; Elmore SW; Souers AJ
Cell Death Dis; 2015 Jan; 6(1):e1590. PubMed ID: 25590800
[TBL] [Abstract][Full Text] [Related]
16. De novo design, synthesis and evaluation of benzylpiperazine derivatives as highly selective binders of Mcl-1.
Ding X; Li Y; Lv L; Zhou M; Han L; Zhang Z; Ba Q; Li J; Wang H; Liu H; Wang R
ChemMedChem; 2013 Dec; 8(12):1986-2014. PubMed ID: 24124106
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.
Pan R; Ruvolo VR; Wei J; Konopleva M; Reed JC; Pellecchia M; Andreeff M; Ruvolo PP
Blood; 2015 Jul; 126(3):363-72. PubMed ID: 26045609
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyquinoline-derived compounds and analoguing of selective Mcl-1 inhibitors using a functional biomarker.
Richard DJ; Lena R; Bannister T; Blake N; Pierceall WE; Carlson NE; Keller CE; Koenig M; He Y; Minond D; Mishra J; Cameron M; Spicer T; Hodder P; Cardone MH
Bioorg Med Chem; 2013 Nov; 21(21):6642-9. PubMed ID: 23993674
[TBL] [Abstract][Full Text] [Related]
19. Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade.
Williams MM; Lee L; Hicks DJ; Joly MM; Elion D; Rahman B; McKernan C; Sanchez V; Balko JM; Stricker T; Estrada MV; Cook RS
Mol Cancer Res; 2017 Mar; 15(3):259-268. PubMed ID: 28039357
[TBL] [Abstract][Full Text] [Related]
20. Structure-based design, synthesis, and evaluation of Bcl-2/Mcl-1 dual inhibitors.
Zhu J; Wang Z; Guo Z; Zhang X; Song T; Guo Y; Ji T; Zhang Z
Arch Pharm (Weinheim); 2020 May; 353(5):e2000005. PubMed ID: 32175625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
